Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 25, 2020
Daily News
September 25, 2020
- Shionogi Delays Saliva-Based COVID-19 Test Launch to December
September 25, 2020
- Astellas, Univ. of Pittsburgh Ink Research Pact for Dry AMD
September 25, 2020
- Taiho Hooks Up with MD Anderson on Refractory Cancers
September 25, 2020
- MHLW to Set Up Study Group to Investigate Formulary Initiatives at Hospitals: Pharmaceutical Management Director
September 25, 2020
- Sawai Can Set Itself Apart from Competitors in Post-80% Generic Era through Development Strategy: President
September 25, 2020
- MHLW Explains Budget Request to LDP Lawmakers, Members Vigilant about Handling of Price Survey Results
September 25, 2020
- MHLW to Request Budgets for Survey on Prescribing Status, Safety of COVID-19 Meds Using MID-NET Database
September 25, 2020
- Daiichi Sankyo Sets Up Subsidiary in Vietnam
September 25, 2020
- Ohara Files Neuroblastoma Drug Dinutuximab in Japan
September 25, 2020
- 5 Improvements when Recruiting Female Employees
September 25, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…